Compare Invesco Solar ETF (TAN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco Solar ETF trades at $52.39, while Zimmer Biomet Holdings Inc trades at $96.48 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Invesco Solar ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| TAN | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $107.71 |
52-Week Low | $36.62 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $52.41, up 1.06% in the last session, amid a bearish technical signal with selling pressure outweighing buys 11 to 4. Recent news highlights solar sector volatility and policy impacts, including new polysilicon tariffs under the Trump administration that may reshape U.S. solar manufacturing dynamics. The ETF's high beta of 1.41 indicates elevated sensitivity to market swings compared to broader energy funds.
Outlook is mixed: tariffs could boost U.S.-focused solar stocks but face headwinds from permit delays and weak residential demand. Risks include regulatory uncertainty and competition from nuclear energy. Analyst sentiment is cautious, with downgrades citing valuation and technical deterioration, though long-term growth drivers like AI energy demand persist.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
